中国耳鼻咽喉头颈外科2016，Vol.23Issue(2)：88-92,5.DOI:10.16066/j.1672-7002.2016.02.008
34βE12、Galectin-3及HBME-1在甲状腺良、恶性结节中的表达差异及临床诊断价值
Expression and diagnostic value of 34βE12, Galectin-3 and HBME-1 in thyroid nodules
摘要
Abstract
[ABSTRACT]OBJECTIVETo study the expressions of 34βE12, Galectin-3 and HBME-1 in thyroid nodules, and to explore its diagnostic value for papillary thyroid carcinoma (PTC).METHODSEn VisionTM immunohistochemical technique was used to detect the expression of 34βE12, Galectin-3 and HBME-1 in 352 thyroid lesions. The correlation between the expressions of the 3 protein markers and clinicopathological characteristics was evaluated. The receiver operating characteristic area under the curve (ROC-AUC) and their index for diagnosis evaluation were also calculated.RESULTSThe positive rates of 34βE12, Galectin-3 and HBME-1 in 246 PTC lesions were significantly higher than those in benign nodules (P<0.001). There was no relationship between the expression of the 3 protein markers and clinicopathological characteristics (eg. gender, age, numbers of lesions, tumor size, capsular invasion, lymph node metastasis, TNM staging). The ROC-AUC of 34βE12, Galectin-3 and HBME-1 for diagnosis of PTC was 0.936, 0.915 and 0.898 respectively. The sensitivity of 34βE12, Galectin-3 and HBME-1 for diagnosis of PTC was 94.3%, 95.5% and 91.1% respectively, while the specificity was 81.1%, 71.7% and 83.0% respectively, and the diagnostic accuracy rate was 90.3%, 88.4% and 88.6% respectively.CONCLUSION The expressions of 34βE12, Galectin-3 and HBME-1 are statistically different between PTC and benign lesions, but no associations are found with clinicopathological characteristics, indicating the three protein markers have important diagnostic value for PTC.关键词
甲状腺结节/甲状腺肿瘤/诊断,鉴别/34βE12/Galectin-3/HBME-1Key words
Thyroid Nodule/Thyroid Neoplasms/Diagnosis, Differential/34βE12/Galectin-3/HBME-1引用本文复制引用
丁金旺,罗定存,周荣璟,罗中尧,何伟,张卧,彭友,赵海菲,徐益平,潘钢..34βE12、Galectin-3及HBME-1在甲状腺良、恶性结节中的表达差异及临床诊断价值[J].中国耳鼻咽喉头颈外科,2016,23(2):88-92,5.基金项目
浙江省杭州市重大科技创新专项项目（20131813A08）和浙江省杭州市医药卫生科技计划项目（2012B004，2014A02）联合资助 （）
